Metastatic Hormone-Sensitive Prostate Cancer: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 March 2024

22 March 2022

18 March 2022

17 December 2021

  • curprev 09:0009:00, 17 December 2021Urology4all talk contribs 11,682 bytes +30 No edit summary undo
  • curprev 08:2708:27, 17 December 2021Urology4all talk contribs 11,652 bytes +11,652 Created page with "<nowiki>*****</nowiki>These notes provide an overview of the treatments in metastatic castrate-sensitive prostate cancer. For notes on selecting treatment for metastatic castrate-sensitive prostate cancer, please see the '''2020 CUA Guideline Notes on Metastatic Castrate-Sensitive Prostate Cancer*****''' == Background == * Incidence of metastatic hormone-sensitive prostate cancer (mHSPC) has been increasing in recent years * Previously, ADT was the only treatment optio..." Tag: Visual edit